EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Azilsartan improves doxorubicin-induced cardiotoxicity via inhibiting oxidative stress, proinflammatory pathway, and apoptosis

Mohammed Al-Chlaihawi, Ali Janabi

Journal of Medicine and Life · 2023-12 · 16 (12) · 1783-1788

DOI: 10.25122/jml-2023-0106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicine and Life, 2023-12. Verfasst von Mohammed Al-Chlaihawi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Kufa Technical Institute, Al-Furat Al-Awsat Technical University, Najaf, Iraq. Hauptthemen laut MEDLINE: Cardiotoxicity, Myocardium, Benzimidazoles, Oxadiazoles. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Azilsartan, a known angiotensin receptor blocker, has shown potential in reducing 24-hour blood pressure and may have protective effects against cardiac complications. Increased oxidative stress in cardiac tissue is directly related to the cardiac complications of doxorubicin. This study investigated whether azilsartan could mitigate doxorubicin-induced cardiotoxicity. We divided 28 male rats into four groups: the control group receiving a standard diet and water, the vehicle group given DMSO orally for two weeks, doxorubicin group receiving 2.5 mg/kg of doxorubicin three times a week for two weeks, and azilsartan group treated with 5 mg/kg/day of azilsartan orally and doxorubicin. Doxorubicin-induced cardiotoxicity was evidenced by a significant increase in TNF-α, IL-1β, MDA, and caspase-3 levels and significantly decreased TAC and Bcl-2 levels in the cardiac tissues of treated rats compared to the DMSO and control groups. Azilsartan significantly decreased doxorubicin-induced cardiotoxicity, as evidenced by a decline in serum levels of both TNF-α and IL-1β. Additionally, MDA significantly decreased in the cardiac tissue, although TAC was significantly increased when comparing the azilsartan group to the group receiving doxorubicin-only. These results suggest that azilsartan effectively reduced doxorubicin-induced cardiotoxicity, likely by mitigating apoptosis, inflammation, and oxidative stress in cardiac tissues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CardiotoxicityMyocardiumBenzimidazolesOxadiazolesRatsMaleAnimalsTumor Necrosis Factor-alphaDimethyl SulfoxideDoxorubicinOxidative StressApoptosis

Stichwörter der Autor:innen

Azilsartanapoptotic factorsdoxorubicin-induced cardiomyopathyinflammatory markersoxidative stress

Substanzen

azilsartanTumor Necrosis Factor-alphaDimethyl SulfoxideDoxorubicinBenzimidazolesOxadiazoles

Autor:innen und Institutionen

  • Department of Pharmacy, Kufa Technical Institute, Al-Furat Al-Awsat Technical University, Najaf, Iraq.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Kufa, Najaf, Iraq.

Zitieren

APA

Al-Chlaihawi, M., & Janabi, A. (2023). Azilsartan improves doxorubicin-induced cardiotoxicity via inhibiting oxidative stress, proinflammatory pathway, and apoptosis. Journal of Medicine and Life, 16(12), 1783-1788. https://doi.org/10.25122/jml-2023-0106

Vancouver

Al-Chlaihawi M, Janabi A. Azilsartan improves doxorubicin-induced cardiotoxicity via inhibiting oxidative stress, proinflammatory pathway, and apoptosis. Journal of Medicine and Life. 2023;16(12):1783-1788. doi:10.25122/jml-2023-0106

BibTeX
@article{AlChlaihawi2023,
  author = {Al-Chlaihawi, Mohammed and Janabi, Ali},
  title = {Azilsartan improves doxorubicin-induced cardiotoxicity via inhibiting oxidative stress, proinflammatory pathway, and apoptosis},
  journal = {Journal of Medicine and Life},
  year = {2023},
  volume = {16},
  number = {12},
  pages = {1783--1788},
  doi = {10.25122/jml-2023-0106}
}
Kostenlos starten →